Podcasts about wegovy

GLP-1 has been making headlines thanks to weight loss medications like Ozempic and Wegovy—but here's the thing: your body already makes GLP-1 naturally. This powerful gut hormone plays a key role in satiety, blood sugar balance, and metabolic health.In this episode, I break down:What GLP-1 is and how your body makes itThe foods and lifestyle habits that naturally support GLP-1 productionThe fascinating role of gut bacteria—like Akkermansia muciniphila and Clostridium butyricum—in lowering inflammation and improving metabolic functionMetabolic daily probiotic linked in my FullscriptWhy GLP-1 is about more than just weight loss, and how it ties into energy, digestion, and long-term healthIf you've been curious about natural ways to support your metabolism, gut health, and energy (without chasing quick fixes), this episode will give you practical, root-cause strategies you can start using today.✨ Takeaway: You don't need to rely on injections—your body is designed to make GLP-1 when you give it the right inputs.

In this episode, Shana Hussin, RDN, shares the replay of her recent webinar on GLP-1 — the hormone behind today's most popular weight loss drugs like Ozempic, Wegovy, and Mounjaro. You'll learn: ✔️ What GLP-1 is and how it works in the body ✔️ Natural ways to increase GLP-1 for fewer cravings, better blood sugar, and fat loss ✔️ Lifestyle habits that decrease GLP-1 and fuel insulin resistance ✔️ The truth about GLP-1 medications: cost, side effects, and sustainability ✔️ How to safely transition off GLP-1 drugs by improving natural GLP-1 and gut health ✔️ The research behind Unimate Yerba Mate and Balance Fiber Matrix — and how they support GLP-1 signaling in the Feel Great System ✨ If you've ever wondered whether you really need expensive GLP-1 medications, or if there's a more sustainable, root-cause solution, this episode is for you. Resources & Links:

Have you heard about people buying weight loss medications from unregulated sources online? The rise of black market weight loss drugs is putting lives at risk. In this episode, I discuss the concerning trend of people purchasing Retatrutide—a medication still in clinical trials—through illegal channels. Known as the "Godzilla Jab" for its potential power, early studies suggest this drug could help people lose up to 24% of their body weight. I explain what Retatrutide is and how it compares to FDA-approved medications like Ozempic, Wegovy, Zepbound, and Mounjaro. We explore why people take dangerous risks with black market drugs, from social media hype to cost concerns and access issues. Most importantly, I share the serious health and legal risks of buying unregulated medications and provide clear guidelines for safely accessing weight loss treatments through licensed providers. Tune in to learn how to protect yourself and make informed decisions about weight loss medications the safe way.   Episode Highlights: What is Retatrutide The dangers of purchasing unregulated medications online Factors driving people to illegal sources Legal risks of buying unapproved drugs and potential health complications from unregulated substances Safe Medication Practices Understanding that medication works best when combined with healthy eating, physical activity, adequate rest, and emotional support   Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd   About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, “Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: kids' A1C and tech access correlation, first generic GLP-1 for weight loss approved, Metformin cuts long covid risk, Tandem Diabetes & Eversense updates, and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Accessibility to modern diabetes technology directly correlates with A1c among children with type 1 diabetes globally. Big, cross-sectional study, conducted in 81 pediatric diabetes centers in 56 countries, found that a greater extent of reimbursement for continuous glucose monitoring (CGM), insulin pumps, glucose meters, and insulin was associated with lower A1c levels. Partha S. Kar, MD, Type 1 Diabetes & Technology lead of the National Health Service England, told Medscape Medical News, “As is now being shown in countries such as UK with widespread uptake of technology, there is now population-wide shift in A1c not seen before.”   He added, “If policymakers are serious about bringing A1c at a population level to sub-7.5% - 8% levels, then without technology it would be incredibly difficult to achieve, in my experience and opinion. Leaving the median A1c of a population at above 7.5%-8% goes with complications so that's a decision regarding investment many will have to make in the near future.”   In an accompanying editorial, Elizabeth R. Seaquist, MD, professor of diabetes, endocrinology, and metabolism and co-director of the Institute for Diabetes, Obesity, and Metabolism at the University of Minnesota, Minneapolis, called it “striking” that access to technology in and of itself was associated with improved glycemic control, given that multidisciplinary team care is also needed to provide education and behavioral or psychological support.     https://www.medscape.com/viewarticle/diabetes-tech-access-linked-a1c-kids-t1d-globally-2025a1000nn6 XX A man with type 1 in Illinois has received the first FDA-approved islet-cell replacement treatment, Lantidra, and  he is now producing his own insulin. The treatment works by restoring the body's beta cells, potentially eliminating the need for insulin injections.   The FDA approved Lantidra (donislecel) in 2023. Lantidra uses donor cells and requires lifelong immunosuppressive drugs.     Lantidra is only available at University of Illinois Chicago Health. Other universities, such as the University of Pennsylvania, continue to do islet cell transplants as part of clinical trials. Early data has shown that a majority of participants in the Lantidra clinical study were able to achieve some level of insulin independence, but it's unclear whether the benefits of donislecel outweigh the treatment's safety risks. Nearly 87 percent of participants reported infection-related adverse events, and post-operation complications included liver lacerations, bruising of the liver (hepatic hematoma), and anemia. One patient died of multi-organ failure from sepsis, which Lantidra maker CellTrans stated was “probably related” to the use of either immunosuppression or study drugs.   In addition, some industry leaders have raised the question of whether it's ethical to commercialize the use of deceased donor islet cells. https://diatribe.org/diabetes-research/first-fda-approved-islet-cell-transplant-performed?utm_campaign=feed&utm_medium=social&utm_source=later   XX Patients in the U.S. now have access to the first generic GLP-1 treatment approved for weight loss as Teva has launched its copycat of Novo Nordisk's injected Saxenda (liraglutide).   The compound, which is a GLP-1 forerunner of Novo's semaglutide products Ozempic and Wegovy, has been approved by the FDA to treat adults with obesity and those who are overweight and have weight-related medical problems.     Saxenda also is endorsed for pediatric patients ages 12 through 17 who are obese and weigh at least 60 kg (132 pounds). The treatment is for both triggering and maintaining weight loss. Saxenda is not the first GLP-1 drug that is available as a generic. In June of last year, Teva also was the first company to launch a knockoff version of Novo's Victoza, which is the same compound as Saxenda but has been approved only for patients with Type 2 diabetes. Sales of the branded versions of both Victoza and Saxenda have declined significantly in recent years as demand for Novo's semaglutide and Eli Lilly's tirzepatide products have skyrocketed. In addition, marketers of compounded products have been aggressively competing for market share in the GLP-1 space. https://www.fiercepharma.com/pharma/saxenda-knockoff-teva-launches-first-generic-glp-1-obesity   XX Metformin could cut the risk of Long COVID by 64% in overweight or obese adults who started the drug within 90 days of infection. The large observational study, published in Clinical Infectious Diseases, analysed health records of over 624,000 UK adults with COVID-19 between March 2020 and July 2023. Among these, nearly 3,000 patients who began metformin treatment soon after diagnosis were tracked for a year. Compared to non-users, their likelihood of developing Long COVID, defined as persistent symptoms 90 days or more after infection, was dramatically lower. https://www.ndtv.com/health/metformin-cuts-risk-of-long-covid-by-64-why-the-diabetes-pill-is-not-for-everyone-9242332 XX Forty-four percent of people age 15 and older living with diabetes are undiagnosed, so they don't know they have it, according to data analysis published Monday in the journal The Lancet Diabetes & Endocrinology. The study looked at data from 204 countries and territories from 2000 to 2023 in a systematic review of published literature and surveys. “The majority of people with diabetes that we report on in the study have type 2 diabetes,” said Lauryn Stafford , the lead author of the study.   “We found that 56% of people with diabetes are aware that they have the condition,” said Stafford, a researcher for the Institute for Health Metrics and Evaluation. “Globally, there's a lot of variation geographically, and also by age. So, generally, higher-income countries were doing better at diagnosing people than low- and middle-income countries.” People under 35 years were much less likely to be diagnosed if they had diabetes than people in middle age or older. Just “20% of young adults with diabetes were aware of their condition,” Stafford said. https://www.cnn.com/2025/09/08/health/diabetes-undiagnosed-half-of-americans-wellness XX A team of Hong Kong scientists is developing an injectable treatment that could potentially improve blood flow in diabetes patients' feet, in the hopes that it will reduce the need for amputation by rebuilding tissue in the arteries.   They also hope to apply the treatment to peripheral artery disease or PAD, a condition caused by the build-up of fatty deposits in arteries that affect blood circulation in the feet. “Traditional treatments for people suffering from poor blood flow in their legs are stent implantation or bypass surgery, which is invasive,” said Wong, who is also the co-founder of a biotechnology company called NutrigeneAI. He said it was his dream to turn research in the academic field into actual clinical treatments. But he added that the team still needed three to four years for further research on the treatment.   https://www.scmp.com/news/hong-kong/health-environment/article/3324671/hong-kong-scientists-developing-new-blood-flow-treatment-aid-diabetes-patients XX   Tandem Diabetes announces Health Canada authorization for distribution of the Tandem t:slim mobile application for Android and iPhone users. The Tandem t:slim mobile app allows users to deliver a bolus from their compatible smartphone, and to wirelessly upload their pump data to the cloud-based Tandem Source platform.1 The app is expected to be available later this year.   The Tandem t:slim mobile app will be available for compatible smartphones in the Apple App Store and Google Play store later in 2025. Once available, Tandem will email eligible customers with instructions on how to download and use the app.  https://www.businesswire.com/news/home/20250904665715/en/Tandem-tslim-Mobile-App-Now-Authorized-by-Health-Canada-for-iPhone-and-Android-Phones   XX Some changes to how the Eversense CGM will be rolled out.. right now it's being distributed by Ascensia Diabetes Care.  Senseonics will take back commercial control of the year long implantable CGM on January 1 in the US and expanding worldwide throughout 2026. The change was a mutual decision, according to the two companies, which said they have signed a memorandum of understanding before a definitive agreement is hammered out by the end of the year. To get started, Senseonics is also set to acquire members of Ascensia's commercial staff—including its CGM president, Brian Hansen, who is slated to become Senseonics' new chief commercial officer. https://www.fiercebiotech.com/medtech/senseonics-retake-eversense-cgm-commercial-control-ascensia-diabetes-care XX Utrecht-based medical device company ViCentra has closed an $85 million Series D round of funding led by Innovation Industries, along with existing investors Partners in Equity and Invest-NL. The round also drew support from EQT Life Sciences and Health Innovations.   The recent capital injection will be used to expand ViCentra's manufacturing capabilities, support regulatory approvals, and strengthen commercial rollout across Europe.   The funds will also be used to launch the next-generation Kaleido 2 patch pump in Europe and prepare for entry into the U.S. market.   The global insulin delivery market is growing quickly due to the increasing number of diabetes cases and demand for effective and user-friendly solutions. The market for insulin pumps is projected to exceed $14 billion by 2034. Patch pumps are the fastest-growing segment, signalling a trend toward compact and wearable devices. And here's where ViCentra is positioned to meet this need, offering a user-friendly, sleek design-led alternative to traditional systems.   Kaleido: design-led insulin delivery Kaleido is the smallest and lightest insulin patch pump developed as a lifestyle product with a particular focus on usability and personalisation.   Designed to feel more like personal technology than a traditional medical device, Kaleido features premium materials, and users can select their own favourite aluminium shells from a range of ten preset colour options.   It integrates with Diabeloop's hybrid closed-loop algorithms (DBLG1 and DBLG2) and is compatible with Dexcom CGM sensors, positioning it within the next generation of automated insulin delivery systems.   “Kaleido is a true disruptor — small, discreet, featherlight, and beautifully designed. It empowers people with diabetes by offering a more personal and distinctive choice in both function and style. Built with empathy and precision, it honours those who live with diabetes every day. With this funding, we can now meet surging European demand and fast-track our entry into the U.S. market. This is a pivotal moment — for ViCentra, and for the community we serve,” said Tom Arnold, Chief Executive Officer at ViCentra.   Improving the quality of life for diabetic patients ViCentra, led by Tom Arnold, is on a mission to improve the lives of those with diabetes.   The company reported that demand for Kaleido in Germany, France, and the Netherlands has already exceeded initial expectations.   ViCentra will present updates on Kaleido at the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD), taking place September 15–19, 2025, in Vienna.   The company plans to engage with clinicians, investors, and strategic partners to further its role in the evolving diabetes care landscape.   “ViCentra is redefining insulin pump therapy with a platform that truly centres the user experience – combining clinical performance with design simplicity and wearability,” commented Caaj Greebe, Partner at Innovation Industries. “At Innovation Industries, we invest in pioneering companies that blend world-class technology with clear commercial potential. ViCentra exemplifies this by delivering a next-generation system addressing the urgent need for better treatment options in diabetes care. We're proud to lead this investment round and partner with Tom and the team as they deepen and expand their presence in Europe and prepare for U.S. entry.”   https://techfundingnews.com/dutch-vicentra-secures-85m-to-bring-insulin-patch-pump-to-more-markets/ XX Luna Diabetes announces they've raised more than 23-million dollars in early venture capital to help continue clinical trials and build out its capacity. This is the company that wants to offer a night time only, tiny, temporary insulin pump – to supplement insulin pen use. According to the company, more than 80% of the improvements in blood sugar from automated insulin delivery systems occur while the user is sleeping. Luna launched a pivotal trial late last year. https://www.fiercebiotech.com/medtech/nighttime-insulin-patch-pump-maker-luna-diabetes-raises-236m   XX Following 15 days and 150 fingerpricks, they're here. The results of the “9 sensor samba“. And what a set of a results…   Well maybe that's overplaying it a little.   Let's just say that the outcome of this n=1 experiment wasn't quite what I expected. One of the established players came out much worse than expected, while a newcomer did a lot better.   Let's dig in, and take a look at the variation. https://www.diabettech.com/cgm/the-nine-sensor-samba-results-revealed/   XX Hard work and perseverance define ranch life, but one man in eastern Montana takes it to another level. At 90, he's still living independently on the ranch he built from the ground up. Even more remarkable? He's a type 1 diabetic.   Bob Delp still begins each day just like he did decades ago, waking up on his ranch near Richey, Montana.   “I always thought if I could ever get a ranch and run a hundred cows, that's what I wanted to do from the time I was a kid,” said Delp.   He made that dream real, the hard way; after coming home from the army, he taught school, hayed for seven cents a bale and saved every cent he could.     “I worked at it real hard because I always felt like it was going to be part of getting me to that ranch that I always wanted,” said Delp.   He did it all while managing type 1 diabetes, a diagnosis that came with few answers and little hope back in the 1950s.   “The doctors tell me being a type 1 diabetic for 66 years isn't supposed to happen. Back then, it was a real challenge,” added Delp.   Statistically, it's almost unheard of. Fewer than 90 people in the world have lived more than 70 years with type 1 diabetes.     Bob credits his late wife, Donna, for helping him beat the odds.   “She has been key in that I always ate on time.”   They've faced their share of storms, both in health and out on the land. Not long after moving to Richey, a heavy snowstorm nearly tore everything apart just after they'd stepped out for dinner.   “If Donna hadn't said it was time to eat, we wouldn't have made it out of there. I guess that's one time that made me happy to have diabetes. And I think that saved us,” said Delp.     Now, he still checks his blood sugar daily but trusts his hands more than high-tech insulin pumps.   “I'm not satisfied with the sensors they have today. I just don't think they're accurate.”   To many, Bob's survival is extraordinary. To him, it's luck.   “The genes are there already, I can't change that so I guess I would have to say just lots of good luck,” said Delp.     And through it all, optimism has been his compass.   “You might fumble the ball, but if you're determined to be a winner, you'll recover that fumble someday,” said Delp.   He still welds nearly every day. Not because he has to, but because it keeps him going.   “As long as I keep doing something like this, I will not be in the nursing home,” said Delp.   https://www.kfyrtv.com/2025/08/09/against-all-odds-montana-man-thrives-with-type-1-diabetes-90/ XX Today, Dexcom is building on this belief and breaking new ground with the launch of its first open call across the U.S. and Canada in search of the next diabetes advocates—giving people with all types of diabetes a once-in-a-lifetime opportunity to raise awareness and share their voice on a global scale in the company's World Diabetes Day campaign (Nov. 14) and beyond.  Who is eligible?: Anyone age 2+ living with all types of diabetes or prediabetes can be nominated by themselves or by someone who knows them. Selected candidates will embody strength, advocacy and pride in living with diabetes or prediabetes. Where and how can I nominate myself or someone I know?: Visit Dexcom.com/WorldDiabetesDay When is the deadline to submit a nomination?: Nominations are open from September 10 through September 19 at 12pm PT. What will the selected candidates experience?:   An invite to participate in a World Diabetes Day photoshoot in Los Angeles to have their unique story featured in Dexcom's World Diabetes Day campaign The ongoing opportunity to attend events, connect with community, and raise diabetes awareness around the world XX The European Association for the Study of Diabetes (EASD) 2025 Annual Meeting will feature major clinical trial results in type 2 diabetes (T2D), type 1 diabetes (T1D), obesity, several new clinical practice guidelines, and much more. The 61st annual EASD meeting will take place on September 15-19, 2025, in Vienna, Austria.   

Send us a textWe've all heard about the dramatic weight-loss results from drugs like Ozempic®, Wegovy®, semaglutide, and tirzepatide, but what aren't you hearing about? In this episode of The Trillium Show, board-certified plastic surgeon Dr. Jason Hall explains the under-the-radar effects these GLP-1 medications can have on your face and skin, including accelerated volume loss, thinning, and changes to your skin's ability to rejuvenate itself.Dr. Hall breaks down:Why these drugs can dramatically change your skin qualityWhat treatments (fat transfer, fillers, lasers, etc.) may help combat this and their limitationsHow to protect your muscle mass and skin health if you're taking or considering GLP-1sIf you're curious about the real impact of GLP-1 medications on aging skin, this episode is a must-listen.

Send us a textAre weight loss drugs like Ozempic, Wegovy, and Mounjaro the miracle breakthrough for obesity and metabolic health—or a dangerous quick fix with hidden risks? In this powerful episode of The Wellness Algorithm with Anshu Bahanda (Wellness Curated), we cut through the hype, celebrity buzz, and TikTok trends to uncover the real science and long-term effects of GLP-1 medications.Joined by leading experts—Dr. Renu Joshi, endocrinologist on the frontlines of obesity and metabolic medicineRebecca Maas, holistic health practitioner and naturopath (author of the upcoming Whole-Body GLP-1 Protocol)Dr. Raj Ragoowansi, renowned plastic surgeon specializing in post-weight-loss transformationsWhether you're considering GLP-1s, already taking them, or simply curious about the wellness conversation reshaping 2025, this episode gives you the science, safety insights, and balanced perspectives you need.✨ Listen now to learn whether weight loss drugs are the future of wellness—or a medical gamble.

Hoy tenemos Consultorio con el Dr. Fernando Pérez Galaz, Médico cirujano especialista en cirugía del aparato digestivo y cirugía bariátrica, y nos va a responder todas las dudas sobre los GLP-1, es decir el Ozempic, Wegovy, Mounjaro y otras marcas más. Hosted on Acast. See acast.com/privacy for more information.

In her annual State of the Union address, European Commission president Ursula von der Leyen has told the European Parliament it needs to regain its independence and bolster its defence capabilities in a 'hostile' world. Also, Danish company Novo Nordisk, the maker of weight-loss drugs Wegovy and Ozempic, has announced plans to cut 9,000 jobs. And the British horse racing industry has gone on strike for the first time ever, in protest at proposed tax rises on bets placed on the sport. You can contact us on WhatsApp or send us a voicenote: +44 330 678 3033.

If you've been hearing all the buzz about GLP-1 medications like Ozempic, Wegovy, or Zepbound, and you're wondering if they could be the right fit for you at midlife, this is the episode to press play on. We brought on nurse practitioner and health optimization expert Amy Wrenn to demystify what GLP-1s actually are, how they work, who they're for, and what you really need to know about taking them during perimenopause and menopause. Amy is passionate, informed, and totally relatable—she cuts through the hype to bring clarity to a topic that's been wrapped in confusion and judgment.In this conversation, we get real about our own experiences, bust some myths, talk side effects (yep, we go there), and explore the broader context of hormone therapy, weight gain, metabolic dysfunction, and the importance of doing what works for your individual body and life. Whether you're curious, cautious, or already on a GLP-1, this is a must-listen packed with valuable insights.  Episode Highlights:[0:00] - Welcoming Amy Wrenn and kicking off our deep dive into GLP-1s [3:10] - What exactly are GLP-1s, and how do they work in your body? [5:00] - Understanding insulin resistance, perimenopause, and why midlife changes everything [6:57] - Real-life examples of "metabolic mayhem" that hits out of nowhere [8:03] - Challenging the lazy stereotype: GLP-1s are not a quick fix [10:08] - The far-reaching benefits: inflammation, PCOS, cognitive health, and more [12:10] - Social media hype vs. safe medical prescribing—know the difference [13:46] - Compounded medications vs. name-brand prescriptions: what to watch for [17:33] - Who qualifies for GLP-1s, and what do providers look for? [20:43] - It's not about skinny—it's about healthy: the real goal of treatment [22:34] - Common side effects: what to expect and how to manage them [25:25] - Nutrition matters: prioritizing protein, avoiding high-fat traps [26:38] - Surprising benefits: reduced alcohol cravings, better food boundaries [28:12] - Coming off GLP-1s: what it looks like, and when it's okay to stay on [31:48] - Does your body adapt over time? Amy explains habituation and dosing [33:32] - The power trio: GLP-1s, HRT, and resistance training [36:08] - Hormone therapy explained: symptom relief vs. long-term prevention [40:51] - Why we're not getting this info from our doctors—and how to change that [42:24] - Where to follow Amy and keep learning more  Links & ResourcesFollow Amy Wrenn, NP on Instagram: https://www.instagram.com/np_wrenn If today's discussion resonated with you or sparked curiosity, please rate, follow, and share "Insights from the Couch" with others. Your support helps us reach more people and continue providing valuable insights. Here's to finding our purposes and living a life full of meaning and joy. Stay tuned for more!Come hang out with us in The Chat, our free community for midlife women, where we keep theconversation going at insightsfromthecouch.org/the-chat. And don't forget todownload our free guide 7 Skills to Master Midlife so you can stop living small, start taking action, andlive the life you really want at insightsfromthecouch.org/midlife-roadmap.

Protests gripped France nationwide on Wednesday as the newly appointed prime minister, Sébastien Lecornu, assumed office. Protesters demonstrated their anger at potentially massive spending cuts, as opposition lawmakers defended their counter-proposals to tackle France's debt and deficit. So what's in their plans? Plus, Danish pharma giant Novo Nordisk announces a plan to cut 9,000 jobs as the maker of Wegovy and Ozempic struggles to turn its fortunes around. 

In this episode of the Game Changing Health podcast, host Gianna speaks with nurse practitioner Chace Franks, an expert in GLP-1 medications. Chase is a nurse practitioner at IVIM Health which is a telehealth company that recently published exciting new data with semaglutide efficacy rivaling tirzepatide with the IVIM model of care involved in treatment. They discuss the evolution of GLP-1s, their effectiveness in weight management, and the role of telehealth in providing accessible healthcare. Chace shares insights from his experience in prescribing GLP-1s, the importance of supportive healthcare providers, and the challenges of insurance coverage. The conversation also touches on the impact of social media in educating patients and the personal experiences of both speakers with GLP-1s. They emphasize the need for patients to advocate for themselves and seek providers who listen to their concerns.  Follow Chase on TikTok: https://www.tiktok.com/@bourbonrx?_t=ZT-8zeFAlyoBEk&_r=1Follow Chace on Instagram: https://www.instagram.com/bourbonrx1?igsh=MWdrZ3g3N2VzZXU1NQ==Check out IVIM here: https://ivimhealth.sjv.io/QjdoYAKeywords:GLP-1, obesity management, telehealth, weight loss, healthcare providers, insurance coverage, patient education, social media, chronic conditions, health investment ✨ The GLP-1 Circle Membership is opening the doors soon, available for all GLP-1 users, it's your hub for dietitian/personal trainer support on your GLP-1 journey for only $99/month. Get first dibs on membership spots here: Join the waitlist

Welcome to Ozempic Weightloss Unlocked. Today we dive into the latest headlines, research, controversies, and the practical realities of Ozempic, a medication originally crafted for type two diabetes that has rocketed into the spotlight for its weight-loss effects.Ozempic, with the active ingredient semaglutide, was approved in the United States in December 2017 to help manage blood sugar in people living with type two diabetes. However, it soon became widely prescribed off-label for weight loss, a trend that only accelerated after the higher-dose version, branded as Wegovy, received federal approval in 2021. According to the Lawsuit Information Center, Ozempic works by mimicking a hormone called glucagon-like peptide 1, helping regulate blood sugar and appetite. Many people using it experience reduced appetite and significant weight reduction.While its popularity continues to grow, so does scientific understanding. A 2025 study presented at the European Society of Cardiology conference revealed that Swiss patients with type two diabetes using oral semaglutide experienced clinically significant drops in both blood sugar and body weight. GlobalData reports that no new safety risks were identified in that trial, supporting ongoing confidence among healthcare professionals.But for those interested only in weight loss, it is not all smooth sailing. Ozempic carries a range of potential side effects. According to King Law, hundreds of lawsuits have been filed in the last year, with plaintiffs claiming they suffered severe complications such as gastroparesis, intestinal blockages, blood clots, and even hair loss. A study published this August found that women on Ozempic experienced twice the rate of hair loss as women who were not taking the drug, while men saw their risk climb by more than half.The United States Food and Drug Administration updated Ozempic's packaging earlier this year to warn about the risk of pancreatitis and severe kidney injuries, including potentially fatal outcomes linked to dehydration from vomiting and diarrhea. The label changes were driven by new clinical trial data and reinforce the importance of medical supervision when using these drugs.Shortages, once a common concern, have eased. The Food and Drug Administration officially took Ozempic off the drug shortage list in February after Novo Nordisk provided reassurance about inventory and supply. That move, however, sparked legal challenges from compounders competing in the market.Unfortunately, enthusiasm for rapid weight loss has also created a black market for Ozempic and similar drugs. The Food and Drug Administration cautions against using compounded or counterfeit versions, which have not undergone review for safety or effectiveness. Some of these unregulated products might be contaminated, mislabeled, or dangerously dosed. Always fill your prescriptions through a licensed pharmacy.For listeners interested in alternatives, exciting research is underway. Purdue University food scientists are investigating foods and supplements that naturally stimulate GLP-1, the hormone Ozempic is designed to mimic. While these approaches will not produce the dramatic weight loss seen with medication, they may help those seeking more natural solutions—especially if someone discontinues their prescription and needs help maintaining a healthy weight.So, where does Ozempic stand today? We have a medication achieving strong results for blood sugar control and weight loss, but one that comes with a profile of side effects still being researched, legal actions underscoring patient concerns, and increased focus on responsible, safe prescribing.Thank you for tuning in to Ozempic Weightloss Unlocked. For more news, insights, and emerging research on the evolving world of weight loss and metabolic health, be sure to subscribe. This has been a quiet please production, for more check out quiet please dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.ai

Claim your complimentary gift of my exclusive mini weight care guide today!Link: Weight Care Guide — Dr. Francavilla Show (thedrfrancavillashow.com)Ever wonder why the same weight loss plan can work wonders for one person but barely move the needle for another?Or why some people respond really well to medications like Wegovy, while others struggle with side effects or see minimal results? That's exactly what precision obesity medicine aims to answer—and today, we're diving into it with one of the world's leading experts.We're joined by Dr. Andres Acosta, a true pioneer in obesity medicine and the creator of the obesity phenotypes concept. He's board-certified in internal medicine, gastroenterology, hepatology, obesity medicine, and nutrition. At the Mayo Clinic, he co-directs the Nutrition and Obesity Research Program and leads the Precision Medicine for Obesity program, focusing on matching the right treatment to the right patient with fewer side effects.Dr. Acosta's research is supported by the National Institutes of Health, with more than 145 peer-reviewed papers in top journals. His work has been featured in The New York Times, TIME, CNN, and NPR, and he's earned “40 Under 40” recognition and co-founded Genomic Sciences—just a glimpse of his many accomplishments.If you've ever felt frustrated by trial-and-error weight loss or wondered if there's a more scientific way to find what actually works for you, you're going to want to hear what Dr. Acosta shares in this episode.Connect with Dr. Acosta:Mayo Clinic: mayu.eduPhenomix Sciences: WebsiteConnect with me:Instagram: doctorfrancavillaFacebook: Help Your Patients Lose Weight with Dr. FrancavillaWebsite: Dr. Francavilla ShowYoutube: The Doctor Francavilla ShowGLP Strong: glpstrong.com

Audio roundup of selected biopharma industry content from Scrip over the business week ended September 5, 2025. In this episode: the US MASH market after Wegovy's approval; AstraZeneca and Mineralys in close hypertension race; United Therapeutics' Phase III win in IPF; Corsera aims to predict and prevent cardiovascular disease; and Ionis's RNA-targeted win in severe hypertriglyceridemia. https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-RKP4E4CFGFGGXBRVXTI73V27U4/ This episode was produced with the help of AI text-to-voice and voice emulation tools. Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

This week on Two Parents & A Podcast, we're joined by Dr. Stephanie Culler — a microbiome scientist and baby gut health expert — to talk about one of the most important (and overlooked (like seriously we had no clue!!!)) parts of raising healthy kids: the gut. Dr. Culler breaks down what gut health actually is, why so many babies are born missing critical microbes, and what that means for things like chronic illness, food allergies, eczema, and even obesity later in life. Dr. Culler shares what parents can do in the first 1,000 days (from pregnancy through toddlerhood) to set their child up for lifelong health, from everyday food choices to the role of antibiotics, and how her groundbreaking study revealed that most babies around the world lack the microbes they need. We also get into practical solutions — like how parents can help restore those microbes through Persephone's new infant & toddler synbiotic (or any pre/probiotic!!!) — plus the foods to focus on (and avoid), and why gut health should be part of every child's standard care. If you're curious about how to give your baby the healthiest start possible, this one's packed with insights you won't want to miss. LOVE YOU GUYS! Timestamps: 00:00:00 Welcome back to Two Parents & A Podcast!  00:02:07 Meet Dr. Stephanie Culler (Microbiome Scientist) 00:03:05 What is gut health—and why it matters for families  00:06:30 The current state of kids' health in the U.S.— chronic illness, food allergies, eczema & obesity  00:10:50 The #1 thing parents can do to help kids live healthier lives  00:13:58 My Baby Biome study reveals a shocking global trend: most babies lack key gut microbes for lifelong health  00:19:34 How do we get babies this bacteria back? Introducing Persephone's infant & toddler synbiotic  00:29:00 Building a better baby gut: recommended foods & foods to avoid  00:33:00 How antibiotics affect gut health in babies & kids (as early as during pregnancy) 00:38:00 Just how important is gut health for kids?—and making it standard of care  00:41:48 LOVE YOU GUYS!  #twoparentsandapod --------------------------------------------------------------- Thank you to our sponsors this week: *OneSkin: Get 15% off OneSkin with the code TWOPARENTS at https://www.oneskin.co/  #oneskinpod *Hers: Start your initial free online visit today at https://www.forhers.com/ALEX for your personalized weight loss treatment options. Hers Weight Loss is not available everywhere. Compounded products are not FDA-approved or verified for safety, effectiveness, or quality. Prescription required. Restrictions apply. Wegovy® and Ozempic® are not compounded. Actual price depends on product and plan purchased. --------------------------------------------------------------- Listen to the pod on YouTube/Spotify/Apple: https://www.youtube.com/@twoparentsandapod https://open.spotify.com/show/7BxuZnHmNzOX9MdnzyU4bD?si=5e715ebaf9014fac https://podcasts.apple.com/us/podcast/two-parents-a-podcast/id1737442386 --------------------------------------------------------------- Follow Two Parents & A Podcast: Instagram | https://www.instagram.com/twoparentsandapod TikTok | https://www.tiktok.com/@twoparentsandapod Follow Alex Bennett: Instagram | https://www.instagram.com/justalexbennett TikTok | https://www.tiktok.com/@justalexbennett Follow Harrison Fugman: Instagram | https://www.instagram.com/harrisonfugman TikTok | https://www.tiktok.com/@harrisonfugman Find our guest: Website | https://www.persephone.bio/ Instagram | https://www.instagram.com/persephone.bio TikTok | https://www.tiktok.com/@persephone.bio --------------------------------------------------------------- Powered by: Just Media House – https://www.justmediahouse.com/ --------------------------------------------------------------- Learn more about your ad choices. Visit megaphone.fm/adchoices

Welcome back to Ozempic Weightloss Unlocked, the podcast dedicated to bringing you the latest news, updates, and insights on Ozempic and its impact on weight, health, and lifestyle.Today, we start with the basics: Ozempic is a medication based on semaglutide, and it is part of a class of drugs called GLP-1 receptor agonists. These drugs work by mimicking a hormone in your gut that helps regulate blood sugar and appetite. According to Purdue University, after a meal, the body naturally releases GLP-1, which helps stimulate insulin production and signals the brain to feel full. Ozempic uses a modified version of this hormone, which not only lowers blood sugar but also reduces appetite, leading to significant weight loss. Clinical studies suggest people can lose between five and twelve percent of their body weight, while also seeing improvements in blood sugar and cardiovascular health.Ozempic is recommended as the first injectable therapy for diabetes by the American Diabetes Association, but most of its headline-grabbing popularity now comes from its off-label use for weight loss. Over fifteen million adults in the United States now use medications like Ozempic, Wegovy, or similar GLP-1-based drugs. The Wall Street Journal reports that this number has been climbing steadily each year.But as more people turn to Ozempic, new challenges and concerns are emerging. The most common side effects are nausea and digestive issues, which can be so severe that up to forty percent of people stop using the drug within the first month, according to Tufts University researchers. Even for those who tolerate Ozempic, there are drawbacks. Experts at Purdue University caution that weight often returns when the drug is discontinued, meaning it is not a permanent fix. Other concerns are rising as well. Mass General Brigham recently published research in JAMA Ophthalmology that links semaglutide to a greater risk of non-arteritic anterior ischemic optic neuropathy, a condition that can cause sudden, permanent blindness. People with diabetes taking semaglutide were over four times more likely to develop this disorder than those who did not.At the same time, there is a lot of online buzz around microdosing, or taking very small amounts of GLP-1 drugs for longevity or anti-aging. The Washington Post and The Independent have both reported that leading experts see no solid scientific evidence that microdosing these drugs provides any benefit or is even safe. Companies marketing microdosing protocols are ahead of the actual science.Researchers at Tufts are now developing new medications that target even more hormone receptors, hoping to be more effective, easier to take, and come with fewer side effects. Their most recent breakthrough aims for a four-in-one drug that tackles multiple hormones tied to metabolism and appetite, with the goal of delivering even greater and longer-lasting weight loss. The hope is that future drugs could treat obesity and simultaneously reduce risks for over one hundred eighty diseases linked to excess weight, including diabetes, cancer, and heart disease.Meanwhile, there are also efforts to stimulate the body's own GLP-1 production naturally, possibly through dietary fibers or future supplements. Purdue researchers believe this could help people maintain weight loss after coming off Ozempic, without the harsh side effects of injections, though results so far show milder weight control than with the actual drug.To sum up, Ozempic has opened a new chapter in metabolic medicine, but there are still risks, unanswered questions, and an ever-changing landscape as science races forward. We will be here to keep you informed with the latest evidence and expert insights.Thank you for tuning in to Ozempic Weightloss Unlocked. If you found this episode helpful, please subscribe so you do not miss our future updates and expert interviews. This has been a quiet please production, for more check out quiet please dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.ai

GLP-1 medications like Ozempic and Wegovy are being marketed everywhere - but who's really being targeted and who's benefitting? Today, we're pulling back the curtain on how these drugs are promoted to the two most vulnerable groups when it comes to disordered eating: young women and menopausal women.We dig into:Why eating disorders are already surging in teens and women in their 20s.How menopause creates a “second wave” of vulnerability and disordered eatingThe role influencers and social media play in normalizing prescriptions as lifestyle upgrades and why affiliate marketing makes this dangerous.Then, we pivot gears to talk about the changing seasons of life. Summer is ending, kids are back to school, and routines are shifting. This doesn't mean starting over - it means adapting your habits to the new season. Whether you're concerned about the rise of diet culture and influencers profiting from your health and insecurities or you just need help navigating your own health pivot as seasons change, this episode cuts through the crap and helps you keep moving forward.Join our Patreon for monthly workouts, challenges, recipes, and to become part of the Cut The Crap Community! Become a member today for exclusive content and to support our podcast: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.patreon.com/cutthecrappodcast⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Thank you Cured Nutrition for sponsoring our Podcast! Just for our listeners, you can receive big savings by using our code 'CTC' when you purchase any Cured product! Pick up some serenity gummies to help you unwind at the end of a long day, flow gummies to help you crush your workout, or even some Salve to help soothe your sore muscles after an intense workout. ⁠Follow the pod: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@cutthecrapwithbethandmatt⁠⁠⁠⁠⁠⁠Follow your hosts:Beth: ⁠⁠⁠⁠⁠⁠@bethferacofitness⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Matt: ⁠⁠⁠⁠⁠⁠@mattlaarfit⁠⁠⁠⁠⁠⁠Send us a DM! Let us know what you think of this one, and with episode ideas! If we use your comment or suggestion, we'll give you a shoutout on the podcast!

This week on Two Parents & A Podcast, we're asking the big parenting (and life) questions: should parenting education be required for every new mom and dad? Why is it so hard to name your kid? And… is breakfast really the most important meal of the day?? (do you guys know where this actually came from??). Before that, we're debating when fall actually starts (September? weather? football?) and how football culture completely changes once you have kids. Plus, an “Unknown Number: The High School Catfish” review (this story is INSANE), and we're back with more ads that have shaped US culture. And in Things We DMed: is AI really the future of dating apps (yes - according to the Bumble founder), and what happens when you cut ultra-processed foods for a month? (+ a practical tip!) LOVE YOU GUYS!!! Timestamps: 00:00:00 Welcome back to Two Parents & A Podcast! 00:00:49 Should parenting education be required for every new mom and dad? 00:03:44 Why is it so hard to name your child? 00:06:45 When does Autumn/Fall start for you? 00:09:55 How football culture shifts once you have kids 00:16:48 “Unknown Number: The High School Catfish” Review 00:22:26 In The Comments: Ads that shaped our culture pt. 2 00:30:00 Things We DMed Eachother: Bumble founder suggests AI is the future of dating apps 00:35:40 Things We DMed Eachother: “We went off ultra-processed foods for a month—here's what really happened” #twoparentsandapod --------------------------------------------------------------- Thank you to our sponsors this week: *GOODLES: Trust us, you need some GOODLES mac & cheese in your life! Pick up GOODLES on your next shopping trip—it's available nationwide at Target and Walmart, plus many other major grocery stores and retailers. And don't forget the new single serve cups! *Hers: Start your initial free online visit today at https://www.forhers.com/ALEX for your personalized weight loss treatment options. Hers Weight Loss is not available everywhere. Compounded products are not FDA-approved or verified for safety, effectiveness, or quality. Prescription required. Restrictions apply. Wegovy® and Ozempic® are not compounded. Actual price depends on product and plan purchased. *Hungryroot: For a limited time get 40% off your first box PLUS get a free item in every box for life. Go to https://www.Hungryroot.com/TWOPARENTS and use code TWOPARENTS --------------------------------------------------------------- Listen to the pod on YouTube/Spotify/Apple: https://www.youtube.com/@twoparentsandapod https://open.spotify.com/show/7BxuZnHmNzOX9MdnzyU4bD?si=5e715ebaf9014fac https://podcasts.apple.com/us/podcast/two-parents-a-podcast/id1737442386 --------------------------------------------------------------- Follow Two Parents & A Podcast: Instagram | https://www.instagram.com/twoparentsandapod TikTok | https://www.tiktok.com/@twoparentsandapod Follow Alex Bennett: Instagram | https://www.instagram.com/justalexbennett TikTok | https://www.tiktok.com/@justalexbennett Follow Harrison Fugman: Instagram | https://www.instagram.com/harrisonfugman TikTok | https://www.tiktok.com/@harrisonfugman --------------------------------------------------------------- Powered by: Just Media House – https://www.justmediahouse.com/ --------------------------------------------------------------- Key words: alex bennett, harrison fugman, justalexbennett, two parents and a podcast, parenting classes, parenting education, baby names, hardest part of naming a baby, football culture with kids, fall vs autumn, high school catfish review, ads that shaped our culture, ultra processed foods, bumble ai dating apps, relationship podcast, parenting podcast, new parents advice Learn more about your ad choices. Visit megaphone.fm/adchoices

Potato intake and diabetes risk.How much daily leucine is required to regain muscle?

I have high LDL cholesterol and a '0' calcium score.  Why does my doctor insist I take a statin?How much vitamin D should I take?  Which product do you recommend?Some doctors assert omega-3s are proinflammatory.  What say you?Study: Magnesium intake may be beneficial in preventing pancreatic cancerDo you have any products to regrow hair?I have a calcium score, but prefer to avoid Lipitor.

#162 The Injection Craze + AI Psychosis Welcome to The Third Hour, your go-to space for Conscious Culture, Conscious Radar, and insights that nourish your curiosity and expand your perspective.This Week:

From Facebook groups to celebrity headlines, woen are promoting GLPs (Ozempic, Wegovy, Mounjaro) as magic fix for menopause. Are we mixing hype with science. Are we being sold another expensive quick fix, and what does this mean for women's health.

비만치료제 위고비(Wegovy), 단순한 다이어트 약일까요?체중 감량은 물론 심혈관 건강까지 개선한다는 최신 임상 결과!이번 영상에서는 국내 최고의 비만·내분비·심장 전문의들이 모여위고비의 임상 효과, 부작용 관리, 실제 환자 사례까지 모두 공개합니다~

✨ My GLP-1 Girlie group program is opening again at the end of September for enrollment for an October start date.

In this episode, Nick Portillo welcomes Oli Ostertag, General Manager at PAR Technologies Operator Cloud. Together, they dive into one of the biggest shifts shaking up the industry: the rise of appetite-suppressing drugs like Ozempic and Wegovy. With more than a quarter of Americans considering these medications, dining habits are changing fast, and restaurants are being forced to adapt.Ollie shares how quick-service brands can turn this disruption into opportunity by offering smaller portions, lower-sugar options, and smarter menus, without sacrificing profitability.TIMESTAMPS00:00 - Intro00:44 - The Impact of Appetite-Suppressing Drugs on Food Service06:59 - The Impact of Consumer Behavior on Food Service Trends19:44 - The Impact of AI on Customer Experience in Food Service22:23 - Optimizing Customer Engagement through Data29:47 - Future Innovations and Product StrategiesRESOURCESPortillo SalesCONTACT Nick: nick.portillo@portillosales.com

Tennis superstar Serena Williams just became the face of a GLP-1 weight loss campaign, and suddenly the conversation around medications like Ozempic, Wegovy, and Mounjaro feels impossible to ignore.             In this episode, I'm sharing the truth about GLP-1s and how they actually work, what I've seen with my own clients who are on them, and the one thing that truly makes weight loss results last.             In this episode, you'll learn:             What GLP-1 medications actually do (and don't do)     Why appetite suppression doesn't solve emotional eating       How muscle loss becomes a hidden risk     The one thing that makes weight loss sustainable long term             This episode is especially for busy, high-achieving women who are curious about GLP-1s but want to know how to use them wisely—or if they even need them at all.            

On The Debbie Nigro Show, I like to dig into stories that make you go, “Wait, what?!” This week's head-turner: “Ozempic Teeth.” Yep, that's the headline making waves, and I knew I had to call in my go-to expert, Dr. John Castanaro of Castanaro Dental in Yonkers, NY, to help get to ‘the tooth of the matter'. What Are “Ozempic Teeth”? GLP-1 medications like Ozempic and Wegovy have taken the world by storm for their weight-loss benefits. But dentists are warning about side effects showing up in the mouth. According to Dr. Castanaro: “It's not the drug itself causing problems—it's the side effects like acid reflux, nausea, vomiting, dry mouth, and sometimes malnutrition.” Those issues can lead to enamel erosion, cavities, swollen gums, and even gingivitis. In short: less saliva = more dental drama. Prevention Is Key The good news? Simple changes can protect your smile: Drink more water. Dehydration is a big culprit. Use products like Biotene (a rinse that coats and protects against dry mouth). Chew sugar-free gum or candies to stimulate saliva. Stay active. Even light walking helps reduce reflux and nausea. Stay on top of dental visits. Dr. Castanaro recommends some patients schedule three cleanings a year instead of two. As he put it: “Prevention and being on top of it—being educated about it—is everything. You can't ignore these signs.” Dentistry's Big Trend Beyond Ozempic teeth, Dr. Castanaro noted a bigger shift: younger generations with fewer cavities are turning to cosmetic upgrades like Invisalign and whitening. Thanks to new tech (hello, 3D printers!), straighter, whiter smiles are now easier and less invasive than ever. My Takeaway Ozempic teeth might sound scary, but the fix is refreshingly simple: hydrate, care for your teeth, and don't skip the dentist. As always, knowledge is power—and I'm glad Dr. Castanaro was here to drop some wisdom (and a little humor). “At the end of the day, prevention and awareness go a long way.” Thanks, Doc. Enlighten yourself in the short podcast of my live conversation with Dr. John Castanaro on The Debbie Nigro Show.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Novo Nordisk's drug Wegovy has successfully reduced cardiovascular risk by 57% compared to tirzepatide. Eli Lilly has terminated two mid-stage trials for a second obesity asset, while Vertex Pharmaceuticals and Enlaza Therapeutics have formed a potential $2 billion partnership to develop drugs for autoimmune diseases. Biogen and Eisai have received FDA approval for the subcutaneous maintenance formulation of Leqvembi. Arrowhead Pharmaceuticals has secured a commitment of up to $2 billion from Novartis for an siRNA Parkinson's program. The FDA's new radiopharma guidance is expected to accelerate the space, and Teva has launched the first generic version of Novo Nordisk's obesity drug Saxenda. The pharmaceutical industry is navigating uncertainty during turbulent times, with companies focusing on innovation and new partnerships to drive progress.The FDA has issued new radiopharma guidance, which former FDA Commissioner Stephen Hahn believes is crucial for cancer therapy. Despite recent investments in radiopharmaceutical therapeutics by big pharma, the FDA's approval of updated COVID-19 vaccines with restrictions contradicts the medical freedom promised by health secretary Robert F. Kennedy Jr. Rare diseases secured four FDA firsts in August, including a win for Novo Nordisk's glp-1 drug WeGovy. Investment in new ALS therapies signals progress after setbacks, with new biotechs and collaborative initiatives showing promise at Bio2025. Other news includes the closure of Appia, Senate summons of Kennedy, updates on COVID-19 vaccines, and Lilly's obesity pill heading to the FDA. Thank you for listening to Pharma and Biotech daily.

We returned from the Labor Day holiday to a spate of intriguing deals, including two that could surpass $2 billion: Vertex's new pact with Enlaza for autoimmune disease—which the Casgevy maker hopes could ease conditioning for the sickle cell/beta thalassemia gene therapy—and Novartis' agreement with Arrowhead for neurodegenerative diseases such as Parkinson's.  But as we look ahead, Thursday's Senate Finance Committee will be the focus this week, as Health and Human Services Secretary Robert F. Kennedy Jr. will answer questions after the ousting of CDC Director Susan Monarez. Her departure is reportedly linked to changes to the regulation of COVID-19 vaccines, for which the FDA last week issued restricted approvals to Moderna, Pfizer/BioNTech and Novavax and rescinded the emergency use authorizations. The next ACIP meeting—where COVID-19 vaccines will be on the agenda—is set for Sept. 18 and 19.   In the weight loss arena, Novo Nordisk presented results from a real-world study this weekend at the European Society of Cardiology Congress in Madrid showing that Wegovy cut the risk of heart attack, stroke or death by 57% compared to Eli Lilly's tirzepatide in people with obesity and cardiovascular disease. The company also continues to throw money into the space, last week inking a $550 million deal with Replicate for RNA-based treatments for obesity and diabetes. Meanwhile, Lilly is dropping studies of one oral obesity candidate as another nears a regulatory filing. Finally, the FDA greenlit the first GLP-1 generic for obesity.   We also discuss reactions to the FDA's new guidance on radiopharma drug development, four recent approvals for rare diseases, and everything you ever wanted to know about SPACs. 

Freeform reveals lineup for '31 Nights of Halloween'; New study on Wegovy and heart disease; Lauren Roberts talks new book, 'Fearful' Learn more about your ad choices. Visit podcastchoices.com/adchoices

Freeform reveals lineup for '31 Nights of Halloween'; New study on Wegovy and heart disease; Lauren Roberts talks new book, 'Fearful' Learn more about your ad choices. Visit podcastchoices.com/adchoices

Visit All Our Links https://linktr.ee/manonthemounjaro GLP-1 Heart Study https://onthepen.substack.com/p/new-study-glp-1-drugs-protect-the

비만치료제 위고비(Wegovy), 단순한 다이어트 약일까요?체중 감량은 물론 심혈관 건강까지 개선한다는 최신 임상 결과!이번 영상에서는 국내 최고의 비만·내분비·심장 전문의들이 모여위고비의 임상 효과, 부작용 관리, 실제 환자 사례까지 모두 공개합니다~

Claim your complimentary gift of my exclusive mini weight care guide today!Link: Weight Care Guide — Dr. Francavilla Show (thedrfrancavillashow.com)Have you ever wondered what it would be like to live without the constant mental chatter about food?For many, those thoughts never seem to stop. From planning the next meal to feeling guilt after eating, food can take up an overwhelming amount of mental space. It's exhausting, and for some, it feels impossible to break free.This ongoing noise, now widely known as food noise, is more than just hunger or cravings—it's the mental weight of always thinking about food, and it can affect every part of daily life. In this episode, we're diving deep into the mental weight of food noise, why it happens, and how dieting history often fuels this constant chatter. We also talk about where the term “food noise” came from, how it's reshaping conversations around weight and eating, and what the latest research is teaching us about the biology behind it.But we don't stop there. We also share practical ways of taking action against food noise—from mindset shifts to medical support—and explain why GLP-1 medications are helping so many people finally quiet the noise, giving them the mental space and freedom they've been missing.If you've ever felt stuck in that cycle, this episode is for you. Listen to the full episode to get the complete discussion and actionable insights.Article link: https://www.nature.com/articles/s41387-025-00382-xConnect with me:Instagram: doctorfrancavillaFacebook: Help Your Patients Lose Weight with Dr. FrancavillaWebsite: Dr. Francavilla ShowYoutube: The Doctor Francavilla ShowGLP Strong: glpstrong.com

Your liver could be silently struggling right now and the good news is, you can turn it around. In this episode, I dive deep into the topic of metabolic dysfunction-associated steatotic liver disease, also known as fatty liver disease. I explain what it is, why the medical community updated the name, and why it matters for long-term health. I highlight who is most at risk, including people with obesity, diabetes, high blood pressure, or high cholesterol and why the condition is often called a “silent disease” since many don't realize they have it. I also break down the potential dangers if it progresses, from inflammation to cirrhosis, and share the encouraging news that it's often reversible with lifestyle changes. My goal is to empower listeners to protect their liver and overall health with small, sustainable changes.  Take control of your health and tune in to this episode to learn how you can prevent, reverse, and protect your liver from fatty liver disease with simple, sustainable steps!   Episode Highlights: What MASLD is and why the name changed from NAFLD Why fatty liver disease is becoming more common and who's most at risk Signs, symptoms, and why it's often called a “silent disease” Potential complications, including inflammation, fibrosis, and cirrhosis How fatty liver is diagnosed through blood tests, imaging, or scans Lifestyle strategies to reverse or prevent progression  The role of managing diabetes, cholesterol, and blood pressure in protecting liver health FDA-approved medications such as Wegovy and others that may help in treatment Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, “Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

Novo Nordisk præsenterer stærke resultater for Wegovy til hjertepatienter. Novo-ansattes aktiegaver er tæt på at gå i 0. Onlinesupermarkedet Nemlig vil være profitable og billige. Hjemmearbejde på tilbagetog i finanssektoren viser undersøgelse. Grænser for topskat fastsat fra 2026. Xi, Putin og Modi mødtes i Shanghai. Vært: Lasse Ladefoged (lasse.ladefoged@borsen.dk)

Want to learn more about starting, managing, or transitioning off GLP-1 medications? Join Physique U to attend this Tuesday's live Q&A with GLP-1 expert Justin Silver (and get the replay plus a free custom nutrition plan): bit.ly/wwpu-free-plan--Are GLP-1 medications like Ozempic, Wegovy, and Mounjaro stealing your hard-earned muscle?The short answer is no, but the reality is more nuanced than many realize.Learn why people experience muscle loss while taking weight loss medications. Weight loss medications can be incredible tools when used properly, but like any tool, they work best when combined with fundamental lifestyle strategies that optimize body composition.Support the show

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: CRISPR modified cell transplant for type 1, risk of T1D if parent has a different type of diabetes, Metformin and the brain, oral GLP-1, and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX A 42-year-old man who has lived most of his life with type 1 diabetes has become the first human to receive a transplant of genetically modified insulin-producing cells. This marks the first pancreatic cell transplant in a human to sidestep the need for immunosuppressant drugs. “This is the most exciting moment of my scientific career,” says cell biologist Per-Ola Carlsson of Uppsala University in Sweden, who helped develop the procedure. The new treatment, he says, “opens the future possibility of treating not only diabetes but other autoimmune diseases.” This procedure uses the gene editing technique, CRISPR, to discourage the auto immune attack on the donor cells. Before the transplant, the participant had no measurable naturally produced insulin and was receiving daily doses of the hormone. But within four to 12 weeks following the transplant, his levels rose slightly on their own after meals—showing that the new beta cells were releasing some insulin in response to glucose. even though the new study is promising, it involved just one participant and is therefore preliminary. And longer-term monitoring is needed to confirm the therapy's safety before it can be offered to more people. She also notes that the injected cells produced only 7 percent of the insulin needed for a person to be fully independent of additional medication. The researchers supplied the recipient with insulin doses to maintain healthy blood sugar levels. While Herold thinks it's still too early to consider this approach for a cure, “these options are now here to change the disease in ways that have never been possible before,” he says. “There's tremendous hope.” https://www.scientificamerican.com/article/type-1-diabetes-patients-insulin-production-restored-with-new-cell/ XX   This one is interesting… a recent study shows that children of mothers with gestational diabetes or fathers with type 2 diabetes have higher chances of developing type 1 diabetes than kids whose parents do not have any type of diabetes. Specifically, the study found that children whose mothers had gestational diabetes during pregnancy were 94% more likely to develop type 1 diabetes compared to children of mothers without diabetes. Similarly, having a father with type 2 diabetes was linked to a 77% higher risk. The study also suggests a possible link between maternal type 2 diabetes and type 1 diabetes in children, although more data are needed to confirm whether the risk is real.   "What is interesting is that type 1 diabetes is a disease of lack of the hormone insulin while gestational diabetes and type 2 diabetes stem mostly from the body's resistance to the hormone. What may be happening is that genes, environments and behaviors that create insulin resistance may also, in some cases, trigger the immune reactions that lead to type 1 diabetes," adds Dr. Dasgupta. A 2019 meta-analysis by researchers at Soochow University in China found that gestational diabetes was linked to a 66% higher risk of type 1 diabetes in children. This new study, which includes more than twice as many studies, offers a robust synthesis of current evidence and shows the risk is even greater than previously estimated. It is also the first meta-analysis to examine the link between paternal type 2 diabetes and type 1 diabetes in offspring. "Several mechanisms may be at play. Families often share lifestyle and eating habits, which can raise the likelihood that children will be affected. But beyond that, high blood sugar levels may also cause biological changes in parents that could increase their children's risk of developing type 1 diabetes," explains Laura Rendon, co-first author of the study, who completed an MSc in experimental medicine at The Institute and, as someone living with type 1 diabetes herself, finds deep personal meaning in conducting this research. For instance, the authors suggest that high blood sugar during pregnancy may stress the fetus's insulin-producing beta cells, reducing their number at birth or making them more vulnerable to damage later in life. It may also trigger epigenetic changes—modifications to proteins and molecules attached to DNA—that increase the risk. Likewise, high blood sugar in fathers with type 2 diabetes may cause epigenetic changes in their sperm, potentially influencing their child's risk of developing type 1 diabetes. https://medicalxpress.com/news/2025-08-diabetes-children-linked-parents.html XX Can a CGM help you lose weight? The company Signos is banking on it – the just got FDA approval for their system, which uses the over the counter Dexcom Stelo. The claim here is that the system will help track how food choices, activity, stress and sleep can all affect metabolism. Signos also works in partnership with the digital nutrition counseling startup Nourish. It currently offers a quarterly subscription plan, including six CGM sensors, for $139 per month. And they tell you don't take any medical actions based on the app's output without consulting a physician. https://www.fiercebiotech.com/medtech/fda-clears-signos-over-counter-cgm-powered-weight-loss-app XX Good news for T1D1, a free mobile app that helps people calculate insulin doses, track daily data, and share insights with healthcare providers. After being pulled off the market with similar apps a few years ago, it's now back and FDA approved. Drew Mendelow created the app after his diagnosis at age 13. He came on the show last year and I'll link his story up in the show notes. Diabetes Center Berne provided the initial funding to support the T1D1 efforts to redesign the app per FDA standards.  Comerge AG , the registered manufacturer, enlisted a team of software engineers, regulatory experts, and design professionals to ensure T1D1 was FDA-ready. Dexcom graciously conducted the Human Factors study to ensure safety and accuracy.  ​ ​T1D1 is now FDA-cleared as a Class II medical device and is the first over-the-counter insulin calculator cleared for individuals aged 2 and older. T1D1 is expected to be live in the AppStore and Google Play Store by October 2025. https://diabetes-connections.com/the-fda-took-down-this-teens-free-bolus-calculator-he-needs-your-help-to-bring-it-back/ XX Metformin has been the standard treatment for type 2 diabetes for more than six decades, yet scientists still do not fully understand how it works. A team from Baylor College of Medicine, working with international collaborators, has now identified an unexpected factor in its effectiveness: the brain. Their findings reveal a brain pathway involved in metformin's glucose-lowering action, pointing to new strategies for treating diabetes with greater precision. The study was published in Science Advances. The researchers concentrated on a small protein called Rap1, located in a region of the brain known as the ventromedial hypothalamus (VMH). They discovered that metformin's ability to lower blood sugar at clinically relevant doses depends on suppressing Rap1 activity in this brain area.   “This discovery changes how we think about metformin,” Fukuda said. “It's not just working in the liver or the gut, it's also acting in the brain. We found that while the liver and intestines need high concentrations of the drug to respond, the brain reacts to much lower levels.”     https://scitechdaily.com/after-60-years-scientists-uncover-hidden-brain-pathway-behind-diabetes-drug-metformin/   XX Looks like GLP-1 pills are moving ahead. Lilly says it's version helped overweight adults with type 2 lose 10% of their body weights and lower A1C. Just two weeks ago, we were talking about how the same drug in people without diabetes had less than the stellar expected results. Orforglipron is a small-molecule pill that is easier to manufacture and package than wildly popular injectable drugs for obesity, such as Lilly's Zepbound and Novo Nordisk's NOVOb.CO rival treatment Wegovy, which are peptide mimics of the appetite-controlling GLP-1 hormone. In the 72-week study of more than 1,600 overweight or obese adults with type 2 diabetes, those who received the 36-milligram highest dose of orforglipron on average shed 10.5% of their weight, or about 23 pounds (10.43 kg), versus 2.2% for those who received a placebo, achieving the main goal of the trial. Patients on the lowest 6 mg dose of the Lilly drug lost 5.5% of their weight. https://www.usatoday.com/story/news/health/2025/08/26/lilly-glp-1-pill-weight-loss/85830686007/ XX     An intervention that combined a low-calorie Mediterranean diet and exercise led to less diabetes incidence in older adults. Men had a greater diabetes risk reduction with the intervention than women. The study was based in Spain, and the diet may not be as easy to adhere to in the U.S. Among nearly 5,000 adults with metabolic syndrome and overweight or obesity in the PREDIMED-Plus trial, those who followed this intervention had a 31% lower risk for type 2 diabetes over 6 years relative to those who received only ad libitum Mediterranean diet advice (aHR 0.69, 95% CI 0.59-0.82). the Mediterranean diet focuses on high intake of plant-based foods, moderate consumption of fish, poultry, and dairy with optional red wine, and low intake of red meats, sweets, and sugar-sweetened beverages. Common foods featured in the diet include extra-virgin olive oil, fruits, vegetables, legumes, nuts, and whole grains. However, Sharon Herring, MD, MPH, and Gina Tripicchio, PhD, MSEd, both of Temple University in Philadelphia, pointed out that this study was conducted solely in Spain, and sticking to this type of diet may be more challenging in countries like the U.S.   "Participants in the study received extra-virgin olive oil to support adherence and retention; in the United States, prices of extra-virgin olive oil have nearly doubled since 2021 due to a combination of factors including climate change, rising production costs, supply chain disruptions, and now tariffs," they noted in an accompanying editorial. "[T]he large number of dietitian contacts during the study may prove difficult to scale broadly in the United States given challenges with health care access and reimbursement for prevention services."         https://www.medpagetoday.com/primarycare/diabetes/117151 XX A group of Canadian researchers has identified an unexpected way to lower blood sugar and protect the liver: by capturing a little-known fuel produced by gut bacteria before it enters the body and causes harm. The findings, published in Cell Metabolism, could open the door to new therapies to treat metabolic diseases like type 2 diabetes and fatty liver disease. Scientists from McMaster University, Université Laval, and the University of Ottawa discovered that a molecule generated by gut microbes can cross into the bloodstream, where it drives the liver to overproduce glucose and fat. By designing a method to trap this molecule in the gut before it reaches circulation, they achieved striking improvements in blood sugar regulation and fatty liver disease in obese mice. https://scitechdaily.com/scientists-discover-a-surprising-new-way-to-fight-diabetes/ XX Dexcom, which specializes in technology for glucose biosensing, will lay off 350 workers, with nearly 200 of them in San Diego, according to the San Diego Union Tribune. The bulk of the local jobs being lost are focused on Dexcom operations and manufacturing. The Dexcom development follows cutbacks to Verily, a life sciences company that is a subsidiary of Alphabet, Google's corporate parent. Verily's work included a project with Dexcom on wearable glucose sensors. CEO Stephen Gillett, in a memo obtained by the publication, said there will be “workforce reductions across Verily.” A representative for Verily confirmed to Business Insider that “we have made the difficult decision to discontinue manufacturing medical devices and will no longer be supporting them going forward.” https://timesofsandiego.com/business/2025/08/27/report-life-sciences-firm-dexcom-lay-off-200-san-diego-workers/ XX Front office changes at Insulet. Eric Benjamin, former chief product and customer experience officer, will take the role of chief operating officer, effective immediately. Manoj Raghunandanan Mu-NOHJ Rug-a-nun-da-nun to the position of chief growth officer, leading Insulet's new growth organization. The appointments are some of CEO Ashley McEvoy's first changes since she was hired in April. The appointments come after McEvoy outlined four priorities for Insulet on an August earnings call:   enhancing the company's commercial capabilities, building Insulet's brand and direct-to-consumer capabilities, driving growth outside of the U.S. and accelerating the pace of innovation. https://www.medtechdive.com/news/insulet-eric-benjamin-manoj-raghunandanan-appointments/758668/ XX   XX Want to highlight The Children's Diabetes Foundation in Colorado – they held a medal ceremony for patients of the Barbara Davis Center who've lived with Type 1 diabetes for 50 years or more. There were 87 medal recipients in the ceremony including Dana Davis, Executive Director of the Children's Diabetes Foundation and the daughter of the founders of the Barbara Davis Center. Davis shared: "When you got Type1 diabetes in the 70s, they thought you shouldn't have children. They thought you weren't going to live past 30 or 40. It was definitely very different," Davis said.   https://www.cbsnews.com/colorado/news/barbara-davis-center-celebrates-colorado-type-1-diabetes-patients-milestone/

If you've ever felt frustrated because your weight loss feels too slow, this episode is for you. Dr. Lisa talks about why so many people quit on themselves when the scale doesn't move fast enough, and why that's often a mistake. You'll hear about Kathy, a client who lost 70 pounds over four years, and why her “snail's pace” transformation may be the smartest way to succeed.Dr. Lisa shares her Top 5 predictors of long-term weight loss success, including why patience matters more than perfection, how showing up consistently changes everything, and why you need to stop giving away your power to the scale.Whether you're using lifestyle changes, medications like Wegovy or Zepbound, or a mix of both, this episode will help you reset your expectations, stay motivated, and finally build the kind of lasting results that stick. Thanks for listening! If you'd like more support during your SMART weight loss & health focused journey, sign up for our FREE newsletter, or check out our program at: www.SmartWeightLossCoaching.com. We would love to help you reach your happy weight, and transform the way you talk to yourself about your body and the number on the scale. Negative thoughts about yourself don't have to take up so much brain space, and we'd be honored to help you reframe those thoughts. Also…We'd be grateful if you'd follow us and share our podcast with your friends & family. We're here to help you improve your health, live longer, healthier, and lose weight the SMART way! This episode was produced by The Podcast Teacher: www.ThePodcastTeacher.com.

GLP-1 medications like Ozempic, Wegovy, and Mounjaro are everywhere right now — but are they really the solution for women over 40, or just another shiny trend? In this episode, I share what I've seen firsthand with clients: women who saw zero results, women who lost muscle mass and ended up terrified about regaining weight, and women who learned how to use GLP-1s as a temporary tool — and then get off them faster, with healthier, sustainable results. I'm also talking about something that really disturbs me: the current fad of coaches and influencers hyping these drugs as just another angle to sell themselves. Midlife women deserve better than gimmicks — they deserve real solutions that last. If you've ever wondered whether GLP-1s are a quick fix or a true foundation for change, this one's for you. ⏱️ Timestamps 0:00 – The GLP-1 hype is everywhere 2:05 – What I've seen with clients on meds 4:25 – The problem with weight loss vs. muscle loss 6:50 – How women successfully titrated off GLP-1s 8:45 – Why influencers push GLP-1s as the new marketing angle 10:55 – The “bucket vs. roof” analogy (quick fix vs. foundation) 14:10 – My final take: GLP-1s as a tool, not the foundation Join my new KICKSTART here: https://go.loridoddy.com/metabolic-kickstart-vsl/   When you're ready, here's how I can help you for FREE: (Community + Support) Join my Lori Doddy's Total Wellness community to get research-backed tips, strategies, and free resources to lose weight and manage menopause like  (Lose Fat) Steal my guide with exact 5 Changes I have all clients make in week 1 of working with us, so they lose weight and drop inches even before we put their customized plan in place. Get the guide for free and use it this week!  (Toned Arms) Use these 6 moves to get toned, strong, sexy arms in 15 minutes a day, 2-3 days a week with this guide to Sexy, Strong Arms. (Email List) Sign up to get my tips and strategies plus exclusive content by getting on the LDL Email List!  

The FDA has granted accelerated approval to semaglutide (Wegovy) as the first drug for metabolic dysfunction–associated steatohepatitis (MASH), showing significant improvements in liver health and weight loss in the phase 3 ESSENCE trial. A systematic review of acetaminophen use in pregnancy found potential risks with long-term or frequent use but confirmed short-term, low-dose use remains appropriate when needed. Finally, an AI model integrating MRI, biomarkers, and clinical data improved prediction of knee osteoarthritis progression, enhancing physician accuracy and suggesting future support for earlier, personalized interventions.

“Welcome to Weight Loss Winformation -  I'm your host, Dr. Connie Stapleton. This is episode 243.  Today's discussion with plastic surgeon Dr. Daniel Kaufman isn't directly related to GLP-1 medications. Yet significant weight loss by any means sometimes leads to body reconstruction. To that end, this episode wraps up our series on GLP-1 agonists! Much to many a person's chagrin, when they lose a significant amount of weight in a short time, they are sometimes left with maybe a little bit – or maybe quite a bit of loose skin. Some people opt to have the skin removed surgically. That is the reason we are speaking today with Dr. Daniel Kaufman, board certified plastic surgeon who shares with us factual and fascinating medical information related to skin removal following weight loss. The Weight Loss Winformation Podcast gives you essential psychological information to help you lose weight and more importantly, to help keep you at a healthy weight for your body! No matter how you are working to lose weight and no matter how much weight you want to lose, Weight Loss Winformation will keep you moving in a positive direction. Let's get started because well… Why Weight? (get it? Pun intended… )?”Resources:BariAfterare: www.bariaftercare.comConnie Stapleton PhD website: www.conniestapletonphd.comBariAftercare website: https://www.conniestapletonphd.com/bariaftercareBariAftercare Facebook page (for members only): https://www.facebook.com/groups/BariAftercareKevin Stephens: Your Bariatric Buddy   https://www.facebook.com/groups/yourbariatricbuddy/peopleInstagram: @cale101 (Caleshia Haynes)Instagram: @therealbariboss (Tabitha Johnson)Instagram @drsusanmitchell (Dr. Susan Mitchell)Instagram: @lauraleepreston (Laura Preston)ProCare Vitamins (10% off with code ConnieStapleton)Rob DiMedio: https://www.busybariatrics.com/Dr. Joan Brugman: drjbrugman@outlook.comDr. Susan Mitchell:https://www.facebook.com/DrSusanMitchellhttps://www.facebook.com/bariatricsurgerystrategiesDr. Daniel Kaufman As Ozempic, Wegovy, and other GLP-1 medications reshape the weight loss industry, many patients are now facing a new challenge: loose, excess skin that diet and exercise can't fix. Board-certified plastic surgeon, Dr. Kaufman specializes in contouring solutions tailored specifically for patients who have experienced significant weight loss through medications like Ozempic. From arm lifts and tummy tucks to advanced skin tightening technologies, Dr. Kaufman offers insight into the physical and emotional journey patients undergo post-weight loss.Instagram: drkaufmanofficial

It's nearly impossible to turn on the television or open a magazine without seeing advertisements for the latest weight loss trend: GLP-1 medications, commonly known as Ozempic, Mounjaro, Wegovy, and Zepbound. Approximately 15 million people are estimated to have tried these drugs for weight loss. However, as with any emerging health trend, it's important to consider whether these medications are safe and cost-effective.What are the risks and benefits of these drugs? Is the pharmaceutical industry providing a quick fix for the approximately 42% (or 100 million) U.S. citizens who are obese? Are these medications the only solution to the obesity epidemic, or are lifestyle and dietary changes essential for long-term success? Dr. Nicole Dorotik joins us in this episode to address these questions and more as we explore the latest trends in the pursuit of health and wellness.Special Guest: Dr. Nicole Dorotik Dr. Nicole Dorotik earned her medical degree from the University of Arizona College of Medicine and completed her residency at Long Beach Memorial Hospital in Long Beach, California. She is board-certified in Family Medicine and has over 20 years of clinical experience. Along with her professional accomplishments, Nicole is the proud mom to three great kiddos. Show notes:Weight Comes Back When You Stop Taking Drugs Like Ozempic, Study Finds.https://www.sciencealert.com/weight-comes-back-when-you-stop-taking-drugs-like-ozempic-study-finds#A new era of weight loss: Mental health effects of GLP-1 drugs.https://www.apa.org/monitor/2025/07-08/weight-loss-drugs-mental-healthRx History: The Rise of GLP-1s.https://www.innovativerxstrategies.com/rx-history-glp1s/Unintended consequences: Weight loss drugs are changing the way consumers buy groceries.https://www.post-gazette.com/business/healthcare-business/2025/08/17/glp1-ozempic-grocery-store-food-price-weightloss/stories/202508070069.

Those injection-free sublingual GLP-1 drops for individualized microdosing—do they actually work? Options for treating stubborn neuropathy; Her new doctor said, “Vitamins are hogwash”—so she fired him; There is hope for tinnitus—via diet and lifestyle; I'm taking German classes, and a new study suggests it'll help me ward off cognitive decline. 

From diabetes care to weight loss trends, GLP-1 agonists are everywhere. In this episode, we unpack the science, social media hype, ethical dilemmas, and side effects surrounding Ozempic, Wegovy, and more. Featuring Dr. Jodie Gee, a Clinical Assistant Professor here at University of Houston College of Pharmacy, and a Ambulatory Care Clinical Pharmacists at Vecino's Denver Harbor Family Clinic, we explore her insights on the role of GLP-1As in patient care. Stay at the end for an in-depth highlight of the newly FDA-approved tirzepatide!

✨ My GLP-1 Girlie group program is opening again at the end of September for enrollment for an October start date.

In this episode of Quah (Q & A), Sal, Adam & Justin coach four Pump Heads via Zoom. Mind Pump Fit Tip: The 3-Step "SBC" Weight-Loss Framework That Works Every Time. (1:48) Ways to safeguard yourself from developing dementia. (23:16) An update on Sal's Journey in Faith & Fitness. (29:50) Methylene Blue's cognitive benefits. (35:21) The little-sibling effect on athleticism. (39:45) Men's skincare market is blowing up! (45:12) The Caltrans “party.” (51:33) #ListenerLive question #1 – Any advice on why my InBody scan showed my body fat went up 6% in a span of 7 months? (56:01) #ListenerLive question #2 –  Is it reasonable to expect a 100-pound jump on my deadlift in a year? (1:07:05) #ListenerLive question #3 – What are some neat, effective, and portable equipment options I should consider having available for my mobile training sessions? Additionally, do you have any business advice or tips for someone making this transition to a mobile personal training model? (1:16:31) #ListenerLive question #4 – What's the best way to support muscle growth and prevent muscle loss while using GLP-1, especially with appetite suppression? What mental shifts do you recommend when transitioning from years of dieting into a performance and strength-driven mindset? (1:25:52) Related Links/Products Mentioned Ask a question to Mind Pump, live! Email: live@mindpumpmedia.com Visit Troscriptions for the exclusive offer for Mind Pump listeners! **Promo code MINDPUMP for 10% off your first order. ** Visit Caldera Lab for an exclusive offer for Mind Pump listeners! **Code MINDPUMP20 for 20% off your first order of their best products. ** August Special: MAPS 15 50% off! ** Code MUSCLE50 at checkout ** Mind Pump #2552: From Plateau to PR… How to Break Through Strength Barriers Mind Pump #2372: Five Steps to a Faster Metabolism Mind Pump #2450: The Smartest Way to Use Protein to Burn Fat & Build Muscle Mind Pump #2287: Bodybuilding 101- How to Bulk and Cut Physically Fit Women Were Less Likely to Develop Dementia, Study Says Sal Di Stefano's Journey in Faith & Fitness – Mind Pump TV Methylene Blue Shows Promise for Improving Short-Term Memory How To Be An Elite Athlete, According To The Data - NPR Caltrans investigates Monterey on-duty party with alcohol, stripper; 10 face firing Visit Seed for an exclusive offer for Mind Pump listeners! **Promo code 25MINDPUMP at checkout for 25% off your first month's supply of Seed's DS-01® Daily Synbiotic** Mind Pump #2566: The Best Way to Measure Progress in the Gym & More (Listener Live Coaching) Mind Pump #1962: How to Hit a Deadlift PR in 30 Days Mind Pump Personal Training – Apply today! Online Personal Training Course | Mind Pump Fitness Coaching ** Approved provider by NASM/AFAA (1.9 CEUs)! Grow your business and succeed in 2025. ** Mind Pump #2597: Before You Take Ozempic, Wegovy, or Mounjaro Listen to This! Building Muscle with Adam Schafer – Mind Pump TV Mind Pump Podcast – YouTube Mind Pump Free Resources People Mentioned IFBB PRO Johnny Sebastian (@_johnnysebastian) Instagram Denis Roberts (@denis_kokushi) Instagram Dr. John Delony (@johndelony) Instagram

In the past couple years, demand has gone wild for drugs like Ozempic – and its cousins, Zepbound, Wegovy, and Mounjaro. For people who had never been able to lose weight before, suddenly the numbers on the scale were plummeting. And everybody wanted to get their hands on them. Now, in most industries, if a product goes viral like this, it's a golden ticket. And thanks to government-granted monopolies designed to encourage innovation, the big drug companies behind these blockbuster injections are currently the only ones allowed to make them.In theory, anyway. But, what if that explosive demand backfired, opening the door to legal knock-offs? You've maybe seen them - copycats advertised as the same thing as Ozempic. So, what's the difference? And just how legal are they? On today's show - a drug that's changing people's lives is also challenging the traditional way we buy and sell medicine.This episode was hosted by Sydney Lupkin and Jeff Guo. It was produced by James Sneed. It was edited by Marianne McCune, fact-checked by Sierra Juarez, and engineered by Gilly Moon and Debbie Daughtry. Alex Goldmark is Planet Money's executive producer.Listen free at these links: Apple Podcasts, Spotify, the NPR app or anywhere you get podcasts.Find more Planet Money: Facebook / Instagram / TikTok / Our weekly Newsletter.Help support Planet Money and hear our bonus episodes by subscribing to Planet Money+ in Apple Podcasts or at plus.npr.org/planetmoney.Music: Source Audio - “Subtly Silly Thug,” “Got The Moves,” and “Vive le Punk”Learn more about sponsor message choices: podcastchoices.com/adchoicesNPR Privacy Policy

In this episode of Quah (Q & A), Sal, Adam & Justin coach four Pump Heads via Zoom. Mind Pump Fit Tip: 8 Fitness & Diet Lies That Will Make You Fat & Unhealthy. (2:08) It's like having a sleep buddy. (27:52) Fart gun. (30:54) Religious revival. (34:02) Reevaluating the streaming services debate. (35:49) AI: The good, the bad, and the ugly. (40:50) Mice infestation. (50:53) Horny stack. (52:46) The podcast world is shifting. (53:45) Shout out to The Diary of a CEO Podcast: The Real Reason You're Still Broke! (and how to escape it) | The Money Making Experts. (55:48) #ListenerLive question #1 – Will I ever be able to get my strength back in my knee, or have I missed my opportunity since I favored it so long? (1:01:33) #ListenerLive question #2 – What advice would you have for building a career as an online fitness coach? (1:16:51) #ListenerLive question #3 – What should my caloric intake be for increasing muscle mass while trying to decrease body fat percentage? (1:26:18) #ListenerLive question #4 – Update from #2566: Can I expect more from my physique, or should I lower my expectations given my circumstances and age? (1:33:13) Related Links/Products Mentioned Ask a question to Mind Pump, live! Email: live@mindpumpmedia.com Visit Eight Sleep for an exclusive offer for Mind Pump Listeners! ** Use the code MINDPUMP to get $350 off your very own Pod 5 Ultra. The best part is that you still get 30 days to try it at home and return it if you don't like it – – Shipping to many countries worldwide. ** Visit Organifi for the exclusive offer for Mind Pump listeners! **Promo code MINDPUMP at checkout for 20% off** August Special: MAPS 15 50% off! ** Code MUSCLE50 at checkout ** Mind Pump #2250: How Eating More Can Make You Leaner (& How Eating Less Can Make You Fatter) Mind Pump #2597: Before You Take Ozempic, Wegovy, or Mounjaro Listen to This! Sore muscles…what does it mean? – Mind Pump Blog Is Gen Z truly experiencing a religious revival? UFC Lands New Home: Paramount+ Gov Pritzker Signs Legislation Prohibiting AI Therapy in Illinois The Diary Of A CEO: The Real Reason You're Still Broke! (and how to escape it) | The Money Making Experts Visit MASSZYMES by biOptimizers for an exclusive offer for Mind Pump listeners! **Code MINDPUMP10 at checkout for 10% off any order. ** Mind Pump # 2555: The Muscle-Building Secrets of Unilateral Training Online Personal Training Course | Mind Pump Fitness Coaching ** Approved provider by NASM/AFAA (1.9 CEUs)! Grow your business and succeed in 2025. ** Is exercise more effective than medication for depression and anxiety? Mind Pump # 1830: Five Steps to Determine Your ideal Caloric Intake Sal Di Stefano's Journey in Faith & Fitness – Mind Pump TV Mind Pump #2566: The Best Way to Measure Progress in the Gym & More (Listener Live Coaching) Elite Trainer Academy – Podcast Mind Pump Podcast – YouTube Mind Pump Free Resources People Mentioned Alex Hormozi (@hormozi) Instagram Codie Sanchez (@codiesanchez) Instagram Daniel Priestley (@danielpriestley) Instagram  

Andrea dives into a topic she's been closely following for a long time: GLP-1 medications like Ozempic, Wegovy, and Mounjaro. As a personal trainer and nutrition coach, she breaks down what GLP-1s are, how they work, their benefits and side effects, and most importantly, whether they serve as a catalyst or a crutch in someone's health journey. Drawing from real-life scenarios, client experiences, and extensive research, Andrea brings a clear, thoughtful perspective to a complex and often controversial subject. This episode offers practical insight for anyone considering GLP-1s or supporting someone who is.Make Fit Simple Podcast is sponsored by KION. Go to Getkion.com/simple for 20% OFFMake it Simple is sponsored by Goodr SunglassesUse code SIMPLE at check out for FREE SHIPPINGhttp://goodr.com/MAKEITSIMPLEStudies: https://diabetesjournals.org/care/article/48/2/292/157724/Efficacy-of-GLP-1-Receptor-Agonists-on-Weight-Loss https://www.amjmed.com/article/S0002-9343%2825%2900059-2/fulltext Improved Dementia https://pmc.ncbi.nlm.nih.gov/articles/PMC8864443/   Decreasing Cardiovascular Disease https://pmc.ncbi.nlm.nih.gov/articles/PMC10739421/ Gastrointestinal Issues https://pmc.ncbi.nlm.nih.gov/articles/PMC10557026/-  Addictions https://www.nature.com/articles/s41591-024-03412-w   PODCASTS on GLP-1 https://podcasts.apple.com/us/podcast/just-ingredients/id1557557205?i=1000679752979 https://podcasts.apple.com/us/podcast/the-dr-tyna-show/id1577258582?i=1000709323014 https://podcasts.apple.com/us/podcast/the-dr-tyna-show/id1577258582?i=1000681609168  Follow the Make Fit Simple Podcast@MakeFitSimplePodcastHave a suggestion for a topic click HEREHave a suggestion for a guest click HERENEW! Leave a question for Andrea HERE on SpeakPipe! Follow Andrea on Instagram@deliciouslyfitnhealthy@dfh.training.picsTraining & Coachinghttps://www.deliciouslyfitnhealthy.com/linksVisit Andrea's Websitewww.deliciouslyfitnhealthy.comProduced by Light On Creative Productions